Lixte Biotechnology Holdings, Inc. (LIXTW) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Pasadena, CA, アメリカ. 現CEOは Geordan G. Pursglove.
LIXTW を有する IPO日 2020-11-27, 2 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $100.55K.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
